实用医学杂志2012，Vol.28Issue(21)：3623-3625,3.DOI:10.3969/j.issn.1006-5725.2012.21.049
长期应用阿托伐他汀钙对再次冠脉介入治疗患者的影响
Effect of long-term pretreatment with atrvastatin on patients undergoing the second percutaneous coronary intervention
张继红 1赵红丽 1张爽2
作者信息
- 1. 110002 沈阳医学院沈洲医院
- 2. 110032 沈阳市,辽宁中医药大学附属医院
- 折叠
摘要
Abstract
Objective To investigate the potential effects of taking atrvastain more than 6 months on CD40L expression and myocardial damage of patients undergoing percutaneous coronary intervention (PCI) once again. Methods A total of 90 patients with unstable angina were randomized into groups of pretreatment with continuous atrvastatin (6 months before the second PCI, atrvastatin group) and without atrvastatin (control group). Creatine kinase-MB (CK-MB), tropoinin I (cTnl), and CD40L level were determined at 12, 24 and 48 hours post the second PCI. Results Before PCI, low level of CD40L was observed in the atrvastatin group. CK-MB level was significantly reduced in the atrvastatin group (P < 0.05) 12 and 24 hours after PCI, cTnls were significantly decreased in the atrvastatin group (P < 0.05) 12, 24 and 48 hours after PCI; CD40 L was significantly reduced in the atrvastatin group (P < 0.05) 24 hours after the PCI. In the control group, the CK-MB upgraded obviously (P < 0.05), and CD40 expression was markedly upregulated at 12 and 24 hours after the operation. Conclusion Long-term pretreatment with atrvastatin may alleviate myocardial damage of patients undergoing PCI and decrease soluble CD40L amplification.关键词
冠状动脉疾病/肌钙蛋白/他汀/CD40Key words
Coronary artery disease/ Troponin/ Statins/ CD40引用本文复制引用
张继红,赵红丽,张爽..长期应用阿托伐他汀钙对再次冠脉介入治疗患者的影响[J].实用医学杂志,2012,28(21):3623-3625,3.
